Lynx Biosciences, Inc

Lynx Biosciences | Reimagining Translational Research with Patient-Centric Models Lynx Biosciences (LynxBio) is reshaping translational and reverse translational research by combining patient-derived cell models, microphysiological systems (MPS), and integrated multi-omic analyses to generate clinically meaningful insights—earlier and without reliance on animal models. Our platform supports high-content functional profiling of antibody and cell-based therapies in complex ex vivo co-cultures. These models preserve the native biology of the tumor and immune microenvironment, enabling more predictive, human-relevant data from the outset. As the field shifts toward more scalable, patient-centric approaches to drug development, LynxBio offers a solution built to meet this moment. We work across oncology and immunology indications to: • Profile therapeutic activity in ex vivo models • Integrate imaging, cytokine analysis, and transcriptomics from the same culture • Identify predictive biomarkers and stratify responders • Uncover resistance mechanisms and guide target refinement Our approach enables the resolution of responder and non-responder profiles, mechanistic biomarkers, and functional signatures from limited clinical material—accelerating the development of novel biologics and cell-engaging therapies. Whether you are advancing bispecific antibodies, cell engagers, or radiotherapeutics, LynxBio offers a plug-in, human-relevant platform to de-risk development, guide patient selection, and inform smarter, earlier decisions. Unlock deeper insight from fewer cells. Partner with LynxBio.